dsdsa

product

Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

Our company since its inception, constantly regards product or service high quality as business life, continually improve creation technology, make improvements to product high-quality and consistently strengthen business total high-quality management, in strict accordance together with the national standard ISO 9001:2000 for 204656-20-2, 540737-29-9, China Peptide, Our company eagerly looks forward to establishing long-term and friendly business partner relationships with clients and businessmen from all over the world.
Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai Detail:

Product name Tofacitinib Citrate
Synonyms (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
CAS No. 540737-29-9
Appearance Off white to white powder
Molecular Formula C16H20N6O.C6H8O7
Molecular Weight 504.50
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Tofacitinib Citrate (CAS #540737-29-9)

ITEMS

STANDARDS

RESULTS

Appearance

Off white to white powder

Off white powder

Identification

HPLC; IR; HNMR

Complies

Solubility

Soluble in DMSO at 100mg/ml, very poorly soluble in ethanol, sparingly soluble in water etc.

Complies

Loss on Drying

≤0.5%

0.12%

Residue on ignition

≤0.1%

0.05%

Heavy metals

≤10ppm

Complies

Related Substances

Diastereomer (RS+SR) ≤0.1%

Single Impurity ≤0.15%

Total impurities ≤1.0%

0.05%

0.14%

0.18%

Enantiomorphism Isomers

≤0.2%

Complies

Residual Solvents

Ethanol ≤5000ppm

Methanol ≤3000ppm

Toluene ≤890ppm

Complies

Citrate Content

36.2%~40%

37.8%

Purity

≥99.0%

99.38%

Assay

60.68%~63.16% of Tofacitinib INN

98%~102% of Tofacitinib Citrate INN

62.04%

 

99.12%

Conclusion:Complies

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures


Related Product Guide:

We generally believe that one's character decides products' top quality, the details decides products' high-quality ,along with the REALISTIC,EFFICIENT AND INNOVATIVE team spirit for Hot-selling China Diclofenac Sodium - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai , The product will supply to all over the world, such as: Kazakhstan, Tunisia, Honduras, Wide selection and fast delivery to suit your needs! Our philosophy: Good quality, great service, keep improving. We've been looking forward that more and more oversea friends join in our family for further development near the future!
  • We are really happy to find such a manufacturer that ensuring product quality at the same time the price is very cheap.
    5 Stars By Ida from Nepal - 2017.08.16 13:39
    The goods are very perfect and the company sales manager is warmful, we will come to this company to purchase next time.
    5 Stars By Megan from Denver - 2017.03.07 13:42
    Write your message here and send it to us